Activity Overview
This Clinical Sessions package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in oncology pharmacy.
The Ambulatory Care Pharmacy Clinical Sessions Recertification Package consists of 4 activities (see table below) and provides up to 6.0 contact hours of continuing pharmacy education and/or recertification credit.
These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by BPS.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Target Audience
These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:
- Targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
- Integration of PARP inhibitors into treatment of breast, prostate, ovarian, and pancreatic cancers
Recertification Credit*
Board-certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ASHP is approved by BPS as a provider for the recertification of BCOP.
|
Learning Activity |
Specialty |
Passing Score |
Credit Information |
| Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer |
BCOP |
79% |
0217-9999-24-067-H01-P
2.0 ACPE/BPS |
| Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapy |
BCOP |
81% |
0217-9999-24-068-H01-P
2.0 ACPE/BPS |
System Technical Requirements
Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites.
View the minimum technical and system requirements for learning activities.
Development
ACCP and ASHP collaborate on oncology pharmacy activities.